Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PRUNE1 | Q86TP1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8834 | 0.85 | POLB (0.47) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL14321232 | 0.85 | MAPT (0.43) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL9775 | 0.85 | POLB (0.47) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL9404 | 0.85 | MEN1 (0.43) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL13635 | 0.85 | MEN1 (0.43) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL13644 | 0.85 | MAPT (0.43) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL9405 | 0.85 | MEN1 (0.43) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL9909 | 0.84 | MAP2K4 (0.41) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL2278793 | 0.83 | MEN1 (0.50) | MEN1KMT2AMAPTNPC1GAA | |
| SCHEMBL11971523 | 0.83 | EGFR (0.55) | MEN1KMT2AMAPTNPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8822485-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130018064-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504330-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063272-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | MEN1 4400/4885KMT2A 1441/4885MAPT 809/4885 |
| US-20130018064-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | MEN1 4504/4885KMT2A 1382/4885MAPT 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.